BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201118
DTSTAMP:20260515T142306
CREATED:20200422T134911Z
LAST-MODIFIED:20200422T134911Z
UID:25203-1605484800-1605657599@www.pharmajournalist.com
SUMMARY:4th Global Pharma R&D AI\, Data Science and Informatics Summit
DESCRIPTION:This Summit is designed to create a collaborative environment in which attendees engaged with the speakers\, sponsors and other delegates in attendance. The meeting agenda has expanded to include: \n\nAI for genomics\, single-cell analysis and target validation.\nAI for predicting patient response.\nAI impacting clinical trials.\nAI for imaging.\nAI for cancer immunotherapy and neurodegenerative diseases\,\nClinical informatics\, data integration\, management and storage\,\nDigital therapeutics\, wearables and sensors.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/4th-global-pharma-rd-ai-data-science-and-informatics-summit/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201118
DTSTAMP:20260515T142306
CREATED:20200423T105853Z
LAST-MODIFIED:20200423T105853Z
UID:25211-1605484800-1605657599@www.pharmajournalist.com
SUMMARY:5th Medicinal Chemistry & Protein Degradation Summit
DESCRIPTION:This Summit will focus its attention to some of the leading issues in Medicinal Chemistry today. This year the conference has expanded its coverage on protein degradation and will have a dedicated track running across both days to explore the cutting-edge research taking place in this exciting area.  \nThe integration of AI and machine learning into the medicinal chemistry process is tackled in another track at the meeting with numerous case studies into how this developing technology is being utilized by industry leaders including Exscientia\, Insitro and Bayer. This compliments the co-located informatics and AI meeting\, which can be attended at any time\, and examines artificial Intelligence in other parts of the drug discovery timeline. \nFinally\, the conference will be looking into recent advances and case studies in phenotypic screening and novel approaches to DNA encoded libraries within a dedicated track. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships.  \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/5th-medicinal-chemistry-protein-degradation-summit/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T142306
CREATED:20200826T130619Z
LAST-MODIFIED:20200826T130619Z
UID:26852-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:2nd Annual Proteome- Targeted Drug Discovery Summit – Digital Event
DESCRIPTION:With about 85% of the proteome currently undrugged\, accessing these targets that are\, at present\, extremely difficult to drug\, has prevented researchers from achieving desired clinical successes. \nThe 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech\, as well as key opinion leaders in academia\, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency\, selectivity\, and physio-chemical properties. \n \nJoin the leading experts from the biopharmaceutical industry and academia to enhance your existing structural\, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline. \nKey Reasons to Attend Include \n\nUtilize next-generation chemical biology platforms for novel target target identification with insights from Biogen\, Merck & AstraZeneca\nExpand the druggable proteome through next-generation screening platforms\, with insight from GSK\, PhoreMost & Ribon Therapeutics\nLeverage innovative chemical probes to accelerate fragment-based lead generation\, with insights from Novartis & The Weizmann Institute of Science\nHarness structure-based computational technologies to successfully target protein-protein interactions\, with insights from RAPT Therapeutics\nGive rise to novel therapeutic modalities to drug the undruggable\, with insights from Silicon Therapeutics& AbbVie\n\nTo know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-proteome-targeted-drug-discovery-summit-digital-event/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T142306
CREATED:20200917T132624Z
LAST-MODIFIED:20200917T132919Z
UID:27122-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:4th Annual Antifibrotic Drug Development Summit
DESCRIPTION:Solving the Translational Drug Development Gap\, From Fibrotic Mechanisms to Clinically Effective Therapeutics. \nNow in its 4th year\, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights\, AFDD will bridge the current translational gap to anti-fibrotic drug development success \nJoin 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs. \nTo know more about 4th Annual Antifibrotic Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-antifibrotic-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T142306
CREATED:20201021T154020Z
LAST-MODIFIED:20201022T115845Z
UID:27582-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:3rd Lifecycle Management for Combination Products Summit
DESCRIPTION:The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development\, to CMC and regulatory affairs\, our experts speakers will help you delve into how to produce a quality and safe combination product\, implications of EU MDR and the final implementation phase of post-market surveillance reporting. \nTo know more about 3rd Lifecycle Management for Combination Products Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-lifecycle-management-for-combination-products-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T142306
CREATED:20200910T131817Z
LAST-MODIFIED:20200917T152111Z
UID:26980-1605571200-1605743999@www.pharmajournalist.com
SUMMARY:Clinical Operations in Oncology Trials USA 2020: Virtual Conference
DESCRIPTION:As the industry grapples with unprecedented challenges\, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology\, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.\n\nTo know more about Clinical Operations in Oncology Trials USA 2020 please click here.
URL:https://www.pharmajournalist.com/event/clinical-operations-in-oncology-trials-usa-2020-virtual-conference/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201120
DTSTAMP:20260515T142306
CREATED:20200923T134148Z
LAST-MODIFIED:20200923T134148Z
UID:27221-1605571200-1605830399@www.pharmajournalist.com
SUMMARY:CRISPR 2.0
DESCRIPTION:Discover the Next Generation of CRISPR Tools to Enhance Specificity\, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality \nCRISPR is one of the most powerful discoveries of the last decade. \nIn a remarkably short space of time\, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox\, which leads to the question: what’s next? \nCRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology\, from the potential of prime editing through to epigenome editing to treat chronic pain. \nDon’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools. \nJoin us to usher in the next generation of safe\, targeted and effective genome editing. \nFor more information on the conference\, visit https://ter.li/ok8ifs \n“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman\, Past attendee\, CRISPR Event Series \n” I greatly enjoyed the diversity and topic coverage of the talks\, thanks for putting together an excellent program!” Christina Kolodzy\, Past attendee\, CRISPR Event Series \n “A high-quality worthwhile conference\, attended by first rate professionals. I learned more than I anticipated I would” Past attendee\, CRISPR Event Series
URL:https://www.pharmajournalist.com/event/crispr-2-0/
LOCATION:Digital Congress
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR